Literature DB >> 8892659

Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo.

G Haas1, U Plikat, P Debré, M Lucchiari, C Katlama, Y Dudoit, O Bonduelle, M Bauer, H G Ihlenfeldt, G Jung, B Maier, A Meyerhans, B Autran.   

Abstract

The vigorous CTL response directed against HIV is considered to be important in reducing HIV viral load, although it is unable to stop ongoing viral replication, which generates new antigenic variants. We analyzed the impact of sequential changes in five epitopes of HIV-1 Nef on CTL recognition in four stable patients. A high rate of variation was found, and in all these patients we could detect CTL specific for 32 out of 36 autologous viral variants occurring in 5 HLA-A2- or HLA-B7-restricted Nef epitopes at two time points. Two distinct patterns for dynamics of CTL responses to viral variation were observed: 1) temporary amplification of viral variants followed by expansion of variant-specific CTL, ultimately leading to the disappearance of 12 out of the 14 initial epitope variants within two years. A second set of viral variants that had replaced the initial ones could also stimulate specific CTL precursors in the context of the same or an alternative HLA molecule; and 2) persistence of 2 viral variants in relatively conserved epitopes despite specific CTL recognition. Therefore, a remarkable flexibility of the immune system allows constant adaptation of CTL to multiple HIV variants and thus elimination of HIV variant-producing cells in slow progressors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8892659

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood.

Authors:  W Herr; E Ranieri; A Gambotto; L S Kierstead; A A Amoscato; L Gesualdo; W J Storkus
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity.

Authors:  Y Lu; R Friedman; N Kushner; A Doling; L Thomas; N Touzjian; M Starnbach; J Lieberman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

3.  Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells.

Authors:  A Samri; G Haas; J Duntze; J M Bouley; V Calvez; C Katlama; B Autran
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

4.  Consequences of cytotoxic T-lymphocyte escape: common escape mutations in simian immunodeficiency virus are poorly recognized in naive hosts.

Authors:  Thomas C Friedrich; Adrian B McDermott; Matthew R Reynolds; Shari Piaskowski; Sarah Fuenger; Ivna P De Souza; Richard Rudersdorf; Candice Cullen; Levi J Yant; Lara Vojnov; Jason Stephany; Sarah Martin; David H O'Connor; Nancy Wilson; David I Watkins
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

5.  High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control.

Authors:  Christoph T Berger; Nicole Frahm; David A Price; Beatriz Mothe; Musie Ghebremichael; Kari L Hartman; Leah M Henry; Jason M Brenchley; Laura E Ruff; Vanessa Venturi; Florencia Pereyra; John Sidney; Alessandro Sette; Daniel C Douek; Bruce D Walker; Daniel E Kaufmann; Christian Brander
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

6.  Comprehensive immunological evaluation reveals surprisingly few differences between elite controller and progressor Mamu-B*17-positive simian immunodeficiency virus-infected rhesus macaques.

Authors:  Nicholas J Maness; Levi J Yant; Chungwon Chung; John T Loffredo; Thomas C Friedrich; Shari M Piaskowski; Jessica Furlott; Gemma E May; Taeko Soma; Enrique J León; Nancy A Wilson; Helen Piontkivska; Austin L Hughes; John Sidney; Alessandro Sette; David I Watkins
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

Review 7.  The spread, treatment, and prevention of HIV-1: evolution of a global pandemic.

Authors:  Myron S Cohen; Nick Hellmann; Jay A Levy; Kevin DeCock; Joep Lange
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

8.  Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients.

Authors:  D Durali; J Morvan; F Letourneur; D Schmitt; N Guegan; M Dalod; S Saragosti; D Sicard; J P Levy; E Gomard
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

9.  Virus dynamics and drug therapy.

Authors:  S Bonhoeffer; R M May; G M Shaw; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

10.  De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection.

Authors:  Todd M Allen; Xu G Yu; Elizabeth T Kalife; Laura L Reyor; Mathias Lichterfeld; Mina John; Michael Cheng; Rachel L Allgaier; Stanley Mui; Nicole Frahm; Galit Alter; Nancy V Brown; Mary N Johnston; Eric S Rosenberg; Simon A Mallal; Christian Brander; Bruce D Walker; Marcus Altfeld
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.